Seeking Alpha

Shares of Halozyme Therapeutics (HALO -12%) plunge after Jefferies cuts its rating to Hold from...

Shares of Halozyme Therapeutics (HALO -12%) plunge after Jefferies cuts its rating to Hold from Buy, noting likely market challenges for three products to be launched by the biopharma company's partners. HALO's royalty revenue is unlikely to drive further appreciation for the stock, the firm adds.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs